Development and evaluation of Nanocarrier-based triple antibiotic aerosol spray for targeted treatment of burns and diabetic foot ulcers

This study focuses on developing a nanocarrier-based aerosol formulation for the topical treatment of burns and diabetic foot ulcers (DFUs), which are often associated with severe complications like infections, amputations, and delayed healing. A Triple Antibiotic Topical Aerosol Spray (TATAS) containing Metronidazole, Mupirocin, and Norfloxacin was formulated to provide broad-spectrum antimicrobial coverage, sustained drug release, and enhanced patient compliance. Eudragit E100 and Isopropyl Myristate (IPM) were selected as the primary polymer and penetration enhancer, respectively, after compatibility and solubility studies. A 3² full factorial design was used to optimize the formulation. Among various batches, batch F7 demonstrated cumulative drug release rates of 79.45% (Metronidazole), 80.75% (Mupirocin), and 79.66% (Norfloxacin) over 24 hours. Physicochemical properties of F7, including a pH of 6.32, viscosity of 3.48 cps, and density of 0.798 g/ml, ensured stability and ease of application. The spray exhibited a uniform pattern with a spray angle of 22° and passed all stability tests under ICH guidelines, with no signs of precipitation or crystal growth. These findings highlight the potential of TATAS as an effective and user-friendly treatment for DFUs and burns, offering targeted drug delivery, sustained action, and improved healing outcomes.